PDF herunterladen
Semin Neurol 2007; 27(2): 159-169
DOI: 10.1055/s-2007-971169
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Tardive Dyskinesia

Karla Soares-Weiser1 , Hubert H. Fernandez2
  • 1Enhance Reviews, Kfar-Saba, Israel
  • 2Department of Neurology, University of Florida/McKnight Brain Institute, Gainesville, Florida
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
27. März 2007 (online)

    Lizenzen und Reprints

ABSTRACT

This article provides up-to-date information regarding clinical manifestations, pathophysiology, and evidence-based treatment for tardive dyskinesia (TD). We conducted a comprehensive literature search, including sources such as the Cochrane Library, EMBASE, and Medline; and we manually searched bibliographic references. We also contacted the authors of each included trial. All randomized clinical trials that compared different types of active interventions with placebo or no intervention in patients with neuroleptic-induced TD were included in our data. Two reviewers independently applied the selection criteria to all identified references, appraised the methodological quality of each trial, and extracted the relevant data. Relative risks and 95% confidence intervals were estimated using the fixed effect model. More than 500 randomized trials evaluating over 90 different interventions to treat TD were identified. From those, 45 trials were included in the current reviews. None of the trials pooled on these reviews found a definitive therapy for TD. Clinicians faced with conditions such as TD should carefully weigh the risks and benefits involved with any given intervention.

KEYWORDS

Tardive dyskinesia - antipsychotics - neuroleptic-induced movement disorders

REFERENCES

  • 1 Schonecker M. Ein eigentumliches Syndrom im oralem Bereich bei Megaphenapplikation.  Nervenarzt. 1957;  28 550-553
    PubMedGoogle Scholar
  • 2 Sigwald J, Bouttier D, Raymondeaud C, Piot C. Quatre cas de dyskinesie facio-bucco-linguo-masticatrice a l'evolution prolongee secondaire a un traitement par less neuroleptiques.  Rev Neurol (Paris). 1959;  100 751-755
    PubMedGoogle Scholar
  • 3 Faurbye A, Rasch P, Peterson P, Brandborg G, Pakkenberg H. Neurological symptoms in pharmacotherapy of psychoses.  Acta Psychiatr Scand. 1964;  40 10-27
    PubMedGoogle Scholar
  • 4 Jankovic J. Tardive syndromes and other drug-induced movement disorders.  Clin Neuropharmacol. 1995;  18 197-214
    CrossrefPubMedGoogle Scholar
  • 5 Yassa R, Lai S. Respiratory irregularity and tardive dyskinesia.  Acta Psychiatr Scand. 1986;  73 506-510
    PubMedGoogle Scholar
  • 6 Fenn D S, Moussaoui D, Hoffman W F et al.. Movements in never-medicated schizophrenics: a preliminary study.  Psychopharmacology (Berl). 1996;  123 206-210
    PubMedGoogle Scholar
  • 7 Fenton W S, Blyler C R, Wyatt R J, McGlashan T H. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients.  Br J Psychiatry. 1997;  171 265-268
    PubMedGoogle Scholar
  • 8 Kane J M, Woerner M, Borenstein M et al.. Integrating incidence and prevalence of tardive dyskinesia.  Psychopharmacol Bull. 1986;  22 254-258
    PubMedGoogle Scholar
  • 9 Barnes T R, Kidger T, Gore S M. Tardive dyskinesia: a 3-year follow-up study.  Psychol Med. 1983;  13 71-81
    PubMedGoogle Scholar
  • 10 Kane J M, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors.  J Clin Psychopharmacol. 1988;  8(suppl) 52S-56S
    PubMedGoogle Scholar
  • 11 Gardos G, Casey D, Cole J et al.. Ten-year outcome of tardive dyskinesia.  Am J Psychiatry. 1994;  151 836-841
    PubMedGoogle Scholar
  • 12 Halliday J, Farrington S, MacDonald S, MacEwan T, Sharley V, McCreadie R. Nithsdale Schizophrenia Survey 23: movement disorders-20 year review.  Br J Psychiatry. 2002;  181 422-427
    CrossrefPubMedGoogle Scholar
  • 13 Kane J M, Smith J M. Tardive dyskinesia: prevalence and risk factors.  Arch Gen Psychiatry. 1982;  39 473-481
    CrossrefPubMedGoogle Scholar
  • 14 Muscettola G, Pampallona S, Barbato G, Casiello M, Bolini P. Persistent tardive dyskinesia: demographic and pharmacological risk factors.  Acta Psychiatr Scand. 1993;  87 29-36
    PubMedGoogle Scholar
  • 15 Jeste D V, Caliguiri M P. Tardive dyskinesia (review).  Schizophr Bull. 1993;  19 303-315
    CrossrefPubMedGoogle Scholar
  • 16 Jeste D V. Tardive dyskinesia in older patients.  J Clin Psychiatry. 2000;  61(suppl 4) 27-32
    Google Scholar
  • 17 Wegner J T, Kane J M. Follow-up study on the reversibility of tardive dyskinesia.  Am J Psychiatry. 1982;  139 368-369
    PubMedGoogle Scholar
  • 18 Klawans H L, Tanner C M, Barr A. The reversibility of “permanent” tardive dyskinesia.  Clin Neuropharmacol. 1984;  7 153-159
    CrossrefPubMedGoogle Scholar
  • 19 Casey D E, Povlsen U J, Meidahl B et al.. Neuroleptic-induced tardive dyskinesia and parkinsonism: change during several years of continuing treatment.  Psychopharmacol Bull. 1986;  22 250-253
    PubMedGoogle Scholar
  • 20 Yagi G, Itoh H. A 10-year follow-up study of tardive dyskinesia with special reference to the influence of neuroleptic administration on the long-term prognosis.  Keio J Med. 1985;  34 211-219
    PubMedGoogle Scholar
  • 21 Gardos G, Cole J O, Haskell D et al.. The natural history of tardive dyskinesia.  J Clin Psychopharmacol. 1988;  8(suppl) 31S-37S
    PubMedGoogle Scholar
  • 22 Fernandez H H, Krupp B, Friedman J H. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up.  Neurology. 2001;  56 805-807
    PubMedGoogle Scholar
  • 23 Hitri A, Weiner W, Borison R et al.. Dopamine binding following prolonged haloperidol pretreatment.  Ann Neurol. 1978;  3 134-140
    CrossrefPubMedGoogle Scholar
  • 24 Klawans H L, Tanner C M, Goetz C G. Epidemiology and pathophysiology of tardive dyskinesia.  Adv Neurol. 1988;  49 185-197
    PubMedGoogle Scholar
  • 25 Steen V M, Lovlie R, MacEwan T, McCreadie R G. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients.  Mol Psychiatry. 1997;  2 139-145
    CrossrefPubMedGoogle Scholar
  • 26 Tsai G, Goff D, Chang R, Flood J, Baer L, Coyle J. Markers of glutamitergic neurotransmission and oxidative stress associated with tardive dyskinesia.  Am J Psychiatry. 1998;  155 1207-1213
    PubMedGoogle Scholar
  • 27 Lohr J B. Oxygen radicals and neuropsychiatric illness: some speculations.  Arch Gen Psychiatry. 1991;  48 1097-1106
    PubMedGoogle Scholar
  • 28 Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.  Cochrane Database Syst Rev. 2006;  (3) CD000459
    PubMedGoogle Scholar
  • 29 El-Sayeh H G, Lyra da Silva J P, Rathbone J, Soares-Weiser K. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia.  Cochrane Database Syst Rev. 2006;  (1) CD000458
    PubMedGoogle Scholar
  • 30 Soares K, Rathbone J, Deeks J. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.  Cochrane Database Syst Rev. 2004;  (4) CD000203
    PubMedGoogle Scholar
  • 31 Soares K V, McGrath J J. Anticholinergic medication for neuroleptic-induced tardive dyskinesia.  Cochrane Database Syst Rev. 2000;  (2) CD000204
    PubMedGoogle Scholar
  • 32 Soares K V, McGrath J J. Vitamin E for neuroleptic-induced tardive dyskinesia.  Cochrane Database Syst Rev. 2001;  (4) CD000209
    PubMedGoogle Scholar
  • 33 Soares-Weiser K, Rathbone J. Calcium channel blockers for neuroleptic-induced tardive dyskinesia.  Cochrane Database Syst Rev. 2004;  (1) CD000206
    PubMedGoogle Scholar
  • 34 Soares-Weiser K, Rathbone J. Calcium channel blockers for neuroleptic-induced tardive dyskinesia.  Cochrane Database Syst Rev. 2000;  (2) CD000204
    PubMedGoogle Scholar
  • 35 Soares-Weiser K V, Joy C. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia.  Cochrane Database Syst Rev. 2003;  (2) CD000208
    PubMedGoogle Scholar
  • 36 Tammenmaa I A, McGrath J J, Sailas E, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia.  Cochrane Database Syst Rev. 2002;  (3) CD000207
    PubMedGoogle Scholar
  • 37 Tammenmaa I A, Sailas E, McGrath J J, Soares-Weiser K, Wahlbeck K. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials.  Prog Neuropsychopharmacol Biol Psychiatry. 2004;  28 1099-1107
    CrossrefPubMedGoogle Scholar
  • 38 Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Higgins JPT, Green S In: The Cochrane Library. Chichester, UK; John Wiley & Sons, Ltd
    Google Scholar
  • 39 Higgins J P, Thompson S G. Quantifying heterogeneity in a meta-analysis.  Stat Med. 2002;  21 1539-1558
    PubMedGoogle Scholar
  • 40 Egger M, Davey-Smith G, Altman D G. Systematic reviews in health care: meta-analysis in context. London; BMJ Publishing Group 2001: 487
    Google Scholar
  • 41 Nordic Dyskinesia Study Group . Effect of different neuroleptics in tardive dyskinesia and parkinsonism: a video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden.  Psychopharmacology (Berl). 1986;  90 423-429
    PubMedGoogle Scholar
  • 42 Double D B, Warren G C, Evans M, Rowlands R P. Efficacy of maintenance use of anticholinergic agents.  Acta Psychiatr Scand. 1993;  88 381-384
    CrossrefPubMedGoogle Scholar
  • 43 Elie R, Morin L, Tetreault L. Effets de l'ethopropazine et du trihexyphenidyle sur quelques parametres du syndrome neuroleptique.  Encephale. 1972;  61 32-52
    PubMedGoogle Scholar
  • 44 Friis T, Christensen T R, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia: a double-blind cross-over study with placebo.  Acta Psychiatr Scand. 1983;  67 178-187
    PubMedGoogle Scholar
  • 45 Gardos G, Cole J O, Rapkin R M et al.. Anticholinergic challenge and neuroleptic withdrawal: changes in dyskinesia and symptom measures.  Arch Gen Psychiatry. 1984;  41 1030-1035
    CrossrefPubMedGoogle Scholar
  • 46 Gerlach J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine.  Psychopharmacology (Berl). 1978;  59 105-112
    CrossrefPubMedGoogle Scholar
  • 47 Greil W, Haag H, Rossnagl G, Ruther E. Effect of anticholinergics on tardive dyskinesia: a controlled discontinuation study.  Br J Psychiatry. 1984;  145 304-310
    CrossrefPubMedGoogle Scholar
  • 48 Klett C J, Caffey Jr E J. Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics.  Arch Gen Psychiatry. 1972;  26 374-379
    PubMedGoogle Scholar
  • 49 Csernansky J G, Tacke U, Rusen D, Hollister L E. The effect of benzodiazepines on tardive dyskinesia symptoms.  J Clin Psychopharmacol. 1988;  8 154-155
    CrossrefPubMedGoogle Scholar
  • 50 Weber S S, Dufresne R L, Becker R E, Mastrati P. Diazepam in tardive dyskinesia.  Drug Intell Clin Pharm. 1983;  17 523-527
    PubMedGoogle Scholar
  • 51 Kojima T, Yamauchi T, Miyasaka M et al.. Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study.  Psychiatry Res. 1992;  43 129-136
    CrossrefPubMedGoogle Scholar
  • 52 Matsunaga T, Ohyama S, Takehara S et al.. The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled study.  Prog Neuropsychopharmacol Biol Psychiatry. 1988;  12 533-539
    CrossrefPubMedGoogle Scholar
  • 53 Buruma O J, Roos R A, Bruyn G W, Kemp B, van-der-Velde E. Tiapride in the treatment of tardive dyskinesia.  Acta Neurol Scand. 1982;  65 38-44
    PubMedGoogle Scholar
  • 54 Hebenstreit G F, Hoffmann H, Hoffmann W, Pittner H. [beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics].  Wien Klin Wochenschr. 1986;  98 388-392
    PubMedGoogle Scholar
  • 55 Beckham B. Lecithin Therapy for Tardive Dyskinesia [dissertation]. Denton; North Texas State University 1981
    Google Scholar
  • 56 Bockenheimer S, Lucius G. [Deanol in tardive dyskinesia: a double-blind study (author's transl)].  Arch Psychiatr Nervenkr. 1976;  222 69-75
    CrossrefPubMedGoogle Scholar
  • 57 de Montigny C, Annable L. Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study.  Psychopharmacology (Berl). 1979;  65 219-223
    CrossrefPubMedGoogle Scholar
  • 58 Gelenberg A J, Dorer D J, Wojcik J D, Falk W E, Brotman A W, Leahy L. A crossover study of lecithin treatment of tardive dyskinesia.  J Clin Psychiatry. 1990;  51 149-153
    PubMedGoogle Scholar
  • 59 George J, Pridmore S, Aldous D. Double blind controlled trial of deanol in tardive dyskinesia.  Aust N Z J Psychiatry. 1981;  15 68-71
    PubMedGoogle Scholar
  • 60 Jackson I. Cholinergic enhancement in tardive dyskinesia.  Current Therapeutic Research. 1978;  24 725-733
    PubMedGoogle Scholar
  • 61 Jackson I V, Nuttall E A, Ibe I O, Perez-Cruet J. Treatment of tardive dyskinesia with lecithin.  Am J Psychiatry. 1979;  136 1458-1460
    PubMedGoogle Scholar
  • 62 Kocher R, Hobi V, Linder M, Studer K. [Treatment with dimethylaminoathanol (deanol) in neuroleptic induced tardive dyskinesia].  Schweiz Arch Neurol Neurochir Psychiatr. 1980;  126 103-109
    PubMedGoogle Scholar
  • 63 Price L. Lecithin Treatment for Tardive Dyskinesia: A Clinical Evaluation [Ph.D. dissertation]. Denton; North Texas State University 1982: 147
    Google Scholar
  • 64 Tarsy D, Bralower M. Deanol acetamidobenzoate treatment in choreiform movement disorders.  Arch Neurol. 1977;  34 756-758
    PubMedGoogle Scholar
  • 65 Yagi G, Kamijima K, Miura S. Meclofenoxate hydrochloride (Lucidril) in tardive dyskinesia: a double-blind placebo-controlled study.  Rinsho Hyoka. 1990;  18 455-479
    PubMedGoogle Scholar
  • 66 Ananth J, Djenderedjian A, Beshay M, Kamal M, Kodjian A, Barriga C. Baclofen in the treatment of tardive dyskinesia.  Curr Ther Res Clin Exp. 1987;  42 111-114
    PubMedGoogle Scholar
  • 67 Burner M, Giroux C, Lheritier C, Garreau M, Morselli P. Preliminary observations on the therapeutic action of progabide in tardive dyskinesia.  Brain Dysfunction. 1989;  2 289-296
    PubMedGoogle Scholar
  • 68 Fisk G G, York S M. The effect of sodium valproate on tardive dyskinesia-revisited.  Br J Psychiatry. 1987;  150 542-546
    CrossrefPubMedGoogle Scholar
  • 69 Gerlach J, Rye T, Kristjansen P. Effect of baclofen on tardive dyskinesia.  Psychopharmacology (Berl). 1978;  56 145-151
    CrossrefPubMedGoogle Scholar
  • 70 Linnoila M, Viukari M, Kietala O. Effect of sodium valproate on tardive dyskinesia.  Br J Psychiatry. 1976;  129 114-119
    PubMedGoogle Scholar
  • 71 Nair N P, Yassa R, Ruiz-Navarro J, Schwartz G. Baclofen in the treatment of tardive dyskinesia.  Am J Psychiatry. 1978;  135 1562-1563
    PubMedGoogle Scholar
  • 72 Stewart R M, Rollins J, Beckam B. Baclofen in tardive dyskinesia patients maintained on neuroleptics.  Clin Neuropharmacol. 1982;  5 365-373
    PubMedGoogle Scholar
  • 73 Thaker G K, Tamminga C A, Alphs L D, Lafferman J, Ferraro T N, Hare T A. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia: reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment.  Arch Gen Psychiatry. 1987;  44 522-529
    PubMedGoogle Scholar
  • 74 Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J. Essential fatty acid supplementation in tardive dyskinesia.  Am J Psychiatry. 1986;  143 912-914
    PubMedGoogle Scholar
  • 75 Mouret J, Khomais M, Lemoine P, Sebert P. Low doses of insulin as a treatment of tardive dyskinesia: conjuncture or conjecture?.  Eur Neurol. 1991;  31 199-203
    PubMedGoogle Scholar
  • 76 Mackay A V, Sheppard G P, Saha B K, Motley B, Johnson A L, Marsden C D. Failure of lithium treatment in established tardive dyskinesia.  Psychol Med. 1980;  10 583-587
    PubMedGoogle Scholar
  • 77 Cookson I B. The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime.  Int Clin Psychopharmacol. 1987;  2 141-149
    PubMedGoogle Scholar
  • 78 Kane J M, Rifkin A, Woerner M et al.. Low-dose neuroleptic treatment of outpatient schizophrenics. I: preliminary results for relapse rates.  Arch Gen Psychiatry. 1983;  40 893-896
    PubMedGoogle Scholar
  • 79 Emsley R, Turner H J, Schronen J, Botha K, Smit R, Oosthuizen P P. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.  J Clin Psychiatry. 2004;  65 696-701
    PubMedGoogle Scholar
  • 80 Glazer W M, Hafez H. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia.  Schizophr Res. 1990;  3 315-320
    CrossrefPubMedGoogle Scholar
  • 81 Kazamatsuri H, Chien C, Cole J. Treatment of tardive dyskinesia. II: short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate.  Arch Gen Psychiatry. 1972;  27 100-103
    PubMedGoogle Scholar
  • 82 Glazer W M, Naftolin F, Morgenstern H, Barnea E R, MacLusky N J, Brenner L M. Estrogen replacement and tardive dyskinesia.  Psychoneuroendocrinology. 1985;  10 345-350
    CrossrefPubMedGoogle Scholar
  • 83 Mosnik D M, Spring B, Rogers K, Baruah S. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients.  Neuropsychopharmacology. 1997;  16 136-146
    CrossrefPubMedGoogle Scholar
  • 84 Adler L A, Peselow E, Rotrosen J et al.. Vitamin E treatment of tardive dyskinesia.  Am J Psychiatry. 1993;  150 1405-1407
    PubMedGoogle Scholar
  • 85 Adler L A, Rotrosen J, Edson R et al.. Vitamin E in the treatment of tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group.  Arch Gen Psychiatry. 1999;  56 836-841
    CrossrefPubMedGoogle Scholar
  • 86 Akhtar S, Jajor T, Kumar S. Vitamin E in the treatment of tardive dyskinesia.  J Postgrad Med. 1993;  39 124-126
    PubMedGoogle Scholar
  • 87 Dabiri L M, Pasta D, Darby J K, Mosbacher D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia.  Am J Psychiatry. 1994;  151 925-926
    PubMedGoogle Scholar
  • 88 Egan M F, Hyde T M, Albers G W et al.. Treatment of tardive dyskinesia with vitamin E.  Am J Psychiatry. 1992;  149 773-777
    PubMedGoogle Scholar
  • 89 Elkashef A M, Ruskin P E, Bacher N, Barrett D. Vitamin E in the treatment of tardive dyskinesia.  Am J Psychiatry. 1990;  147 505-506
    PubMedGoogle Scholar
  • 90 Lam L C, Chiu H F, Hung S F. Vitamin E in the treatment of tardive dyskinesia: a replication study.  J Nerv Ment Dis. 1994;  182 113-114
    PubMedGoogle Scholar
  • 91 Lohr J B, Caligiuri M P. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.  J Clin Psychiatry. 1996;  57 167-173
    PubMedGoogle Scholar
  • 92 Sajjad S H. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses.  Int Clin Psychopharmacol. 1998;  13 147-155
    PubMedGoogle Scholar
  • 93 Schmidt M, Meister P, Baumann P. Treatment of tardive dyskinesias with vitamin E.  Eur Psychiatry. 1991;  6 201-207
    PubMedGoogle Scholar
  • 94 Soares K V, McGrath J J. The treatment of tardive dyskinesia: a systematic review and meta-analysis.  Schizophr Res. 1999;  39 1-16 discussion 17-18
    CrossrefPubMedGoogle Scholar
  • 95 Weber S S, Dufresne R L, Becker R E, Mastrati P. Diazepam in tardive dyskinesia.  Drug Intell Clin Pharm. 1983;  17 523-527
    PubMedGoogle Scholar

Hubert H FernandezM.D. 

Program Director, Neurology Residency Training Program, University of Florida/McKnight Brain Institute

PO Box 100236, Gainesville, FL 32610

      >